Anti-hPD1-Pem-hIgG2 features the constant region of the human IgG2 isotype and the variable region of pembrolizumab. Pembrolizumab is a humanized IgG4 monoclonal antibody that contains an engineered hinge region mutation (S228P) designed to prevent exchange of IgG4 molecules. This antibody targets the PD-1 receptor found on activated T cells, B cells, and myeloid cells. Under normal physiological conditions, PD-1 negatively regulates T cell activation thereby preventing autoimmunity [1]. Under pathological conditions, cancer cells produce PD-L1 (programmed cell death 1 ligand 1), the agonist that binds and activates PD-1. Activated PD-1 enables the cancer cells to evade the immune system. Pembrolizumab binds and blocks the activation of the PD-1 receptor, thereby resulting in the activation of T cells [2]. Pembrolizumab has been approved by the FDA for the treatment of metastatic malignant melanoma, and is currently under regulatory review in the EU [3].

Human IgG2 is the second most common antibody present in serum. This isotype is resistant to cleavage by proteolytic enzymes, due to a short hinge region. Human IgG2 displays low complement-dependent cytotoxicity (CDC) and very low antibody-dependent cell-mediated cytotoxicity (ADCC).

Anti-hPD1-Pem-hIgG2 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography.


Specificity: Targets cells expressing human PD-1
Clonality: Monoclonal antibody
Isotype: Human IgG2
Source: CHO cells
Formulation: 0.2 μm filtered solution in a sodium phosphate buffer with glycine, saccharose and stabilizing agents.
Purity: Purified by affinity chromatography with protein G

Applications: Anti-hPD1-Pem-hIgG2 binds and blocks ligand activation of the PD-1 receptor found on the surface of activated T cells.

Quality control:
- The recognition of PD-1 with this antibody has been tested using flow cytometry.
- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.


• 100 µg anti-hPD1-Pem-hIgG2 purified antibody, provided azide-free and lyophilized


  1. McDermott D. & Atkins M. 2013. PD-1 as a potential target in cancer therapy. Cancer Med. 2(5): 662–673.
  2. Tumeh PC. et al., 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 515(7528):568-71.
  3. Poole RM., 2014. Pembrolizumab: first global approval. Drugs. 4(16):1973-81.



Description Monoclonal human IgG2 antibody against human PD-1
Cat. Codehpd1pe-mab2
Unit Size100 µg
Price For price or distributor address,
please select your country
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "".